These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8879560)

  • 1. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.
    Komai T; Higashida S; Sakurai M; Nitta T; Kasuya A; Miyamaoto S; Yagi R; Ozawa Y; Handa H; Mohri H; Yasuoka A; Oka S; Nishigaki T; Kimura S; Shimada K; Yabe Y
    Bioorg Med Chem; 1996 Aug; 4(8):1365-77. PubMed ID: 8879560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
    J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
    Mühlman A; Classon B; Hallberg A; Samuelsson B
    J Med Chem; 2001 Oct; 44(21):3402-6. PubMed ID: 11585445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA.
    Sakurai M; Higashida S; Sugano M; Komai T; Yagi R; Ozawa Y; Handa H; Nishigaki T; Yabe Y
    Bioorg Med Chem; 1994 Aug; 2(8):807-25. PubMed ID: 7894975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element.
    Raju B; Deshpande MS
    Biochem Biophys Res Commun; 1991 Oct; 180(1):181-6. PubMed ID: 1930214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
    Kaltenbach RF; Klabe RM; Cordova BC; Seitz SP
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2259-62. PubMed ID: 10465557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.
    Alterman M; Andersson HO; Garg N; Ahlsén G; Lövgren S; Classon B; Danielson UH; Kvarnström I; Vrang L; Unge T; Samuelsson B; Hallberg A
    J Med Chem; 1999 Sep; 42(19):3835-44. PubMed ID: 10508432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV; Lunney EA; Para KS; Tummino PJ; Ferguson D; Hupe D; Domagala JM; Erickson JW
    Drug Des Discov; 1996 Apr; 13(3-4):15-28. PubMed ID: 8874041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
    Chen P; Cheng PT; Alam M; Beyer BD; Bisacchi GS; Dejneka T; Evans AJ; Greytok JA; Hermsmeier MA; Humphreys WG; Jacobs GA; Kocy O; Lin PF; Lis KA; Marella MA; Ryono DE; Sheaffer AK; Spergel SH; Sun CQ; Tino JA; Vite G; Colonno RJ; Zahler R; Barrish JC
    J Med Chem; 1996 May; 39(10):1991-2007. PubMed ID: 8642558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
    Senese CL; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
    Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors.
    Randad RS; Lubkowska L; Silva AM; Guerin DM; Gulnik SV; Yu B; Erickson JW
    Bioorg Med Chem; 1996 Sep; 4(9):1471-80. PubMed ID: 8894104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.
    Blum A; Böttcher J; Dörr S; Heine A; Klebe G; Diederich WE
    J Mol Biol; 2011 Jul; 410(4):745-55. PubMed ID: 21762812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.